EMPAGEN L 5/25MG TABLET

EMPAGEN L 5/25MG TABLET is a combination medication containing Linagliptin and Empagliflozin. It is used for the treatment of type 2 diabetes.

Uses:

• Improving blood sugar control
• Reducing the risk of cardiovascular events (such as heart attack or stroke) in patients with type 2 diabetes
• Reducing the progression of kidney disease in patients with type 2 diabetes and kidney disease

Benefits:

• EMPAGEN L 5/25MG TABLET provides dual action in controlling blood sugar levels and reducing the risk of cardiovascular events.
• It is a convenient way to take two different medications in one tablet, making it easier for patients to follow their treatment regimen.
• It may also improve kidney function in patients with type 2 diabetes and kidney disease.

Side Effects:

• Nausea
• Diarrhea
• Dehydration
• Urinary tract infections
• Yeast infections
• Low blood pressure
• Kidney problems
• Hypoglycemia (low blood sugar) in some patients

It is important to note that not all patients will experience side effects and the severity may vary. If you experience any severe or persistent side effects, you should seek medical attention immediately.

Before taking EMPAGEN L 5/25MG TABLET, it is important to inform your doctor about any medical conditions, medications, or allergies you may have. Also, inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.

EMPAGEN L 5/25MG TABLET is a prescription medication and should be used as directed by your doctor. It is important to follow the recommended dosage and not change it without first consulting your doctor.

In conclusion, EMPAGEN L 5/25MG TABLET is a combination medication that can effectively improve blood sugar control and reduce the risk of cardiovascular events in patients with type 2 diabetes. However, it is important to be aware of potential side effects and to always inform your doctor about any medical conditions or medications you are taking.

Delivery within 2 to 3 working days from khasmart.pk after confirmation.